Atomoxetine: a new treatment for Attention Deficit/Hyperactivity Disorder (ADHD) in children and adolescents (Q46686811)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16142049%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

review article

1 reference

title

Atomoxetine: a new treatment for Attention Deficit/Hyperactivity Disorder (ADHD) in children and adolescents (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16142049%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

1 reference

1 reference

attention deficit hyperactivity disorder

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16142049%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

author name string

P Fourneret

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16142049%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

M Wohl

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16142049%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

J-P Rénéric

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16142049%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

publication date

1 May 2005

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16142049%20AND%20SRC:MED&resulttype=core&format=json

L'Encephale: revue de psychiatrie clinique biologique et therapeutique

6 January 2020

number of pages

12

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16142049%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

volume

31

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16142049%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16142049%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

page(s)

337-348

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16142049%20AND%20SRC:MED&resulttype=core&format=json

Catecholamine modulation of prefrontal cortical cognitive function

6 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0013-7006%2805%2982399-1

Effect of potent CYP2D6 inhibition by paroxetine on atomoxetine pharmacokinetics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0013-7006%2805%2982399-1

Efficacy of atomoxetine versus placebo in school-age girls with attention-deficit/hyperactivity disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0013-7006%2805%2982399-1

Attention-deficit/hyperactivity disorder (ADHD) as a noradrenergic disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0013-7006%2805%2982399-1

Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0013-7006%2805%2982399-1

Toward a pathophysiology of attention-deficit/hyperactivity disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0013-7006%2805%2982399-1

Effect of hepatic impairment on the pharmacokinetics of atomoxetine and its metabolites

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0013-7006%2805%2982399-1

The revised Conners' Parent Rating Scale (CPRS-R): factor structure, reliability, and criterion validity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0013-7006%2805%2982399-1

Localization of rat brain binding sites for [3H]tomoxetine, an enantiomerically pure ligand for norepinephrine reuptake sites

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0013-7006%2805%2982399-1

Comparison of the subjective, physiological, and psychomotor effects of atomoxetine and methylphenidate in light drug users

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0013-7006%2805%2982399-1

Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open-label trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0013-7006%2805%2982399-1

Canadian-French, German and UK versions of the Child Health Questionnaire: methodology and preliminary item scaling results

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0013-7006%2805%2982399-1

Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0013-7006%2805%2982399-1

Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0013-7006%2805%2982399-1

Identification of the human cytochromes P450 responsible for atomoxetine metabolism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0013-7006%2805%2982399-1

Disposition and metabolic fate of atomoxetine hydrochloride: the role of CYP2D6 in human disposition and metabolism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0013-7006%2805%2982399-1

Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0013-7006%2805%2982399-1

An open-label, dose-ranging study of atomoxetine in children with attention deficit hyperactivity disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0013-7006%2805%2982399-1

Effectiveness and tolerability of tomoxetine in adults with attention deficit hyperactivity disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0013-7006%2805%2982399-1

Pharmacotherapy of attention-deficit hyperactivity disorder across the life cycle

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0013-7006%2805%2982399-1

Cardiovascular effects of atomoxetine in children, adolescents, and adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0013-7006%2805%2982399-1

Atomoxetine pharmacokinetics in children and adolescents with attention deficit hyperactivity disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0013-7006%2805%2982399-1

10.1016/S0013-7006(05)82399-1

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16142049%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

1 reference